Company intelligence / Profile preview

Elucida Oncology, Inc.

Monmouth Junction, New Jersey, United Statescience.com ↗

Ownership: Private
Development stage: Other

Overview

Elucida Oncology ceased operations in late 2024 due to lack of funding. Before closing, the company had completed the dose escalation portion of its Phase 1/2 trial for ELU001, its lead FRα-targeted CDC, and had begun expansion cohorts. The drug showed a positive safety profile with manageable side effects and preliminary anti-tumor activity across all levels of FRα expression in heavily pre-treated patients.

Therapeutic areas: OncologyHematology
Modalities: C'Dot drug conjugates (CDCs)Small molecules
Industry: Biotech

Drug pipeline

3 assets

copper cu 64 NOTA-PSMAi-PEG-Cy5.5-C' dots

2 more assets in the full pipeline.

Request access →

Partnerships

Research collaboration with a top 10 pharmaceutical company

Beyond the preview

Go deeper on Elucida Oncology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elucida Oncology, Inc..

Explore the full profile